assessment of the effect of tranexamic acid on intraoperative blood loss in patients who undergo the surjery which the skull is opened in, for tumor excision

assessment of the effect of tranexamic acid on intraoperative blood loss in patients undergoing craniotomy for tumor excision

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016122631573N1

Enrollment

Registered

2017-03-21

Start date

2016-07-25

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumor. Other specified disorders of brain in diseases classified elsewhere

Interventions

Intervention 1: Control group: Placebo is injected to the patients of this group. Twenty five Patients with brain tumor, age range of 18 to 60 years and ASA class 1 or 2 are in this group. Saline grou

Treatment - Drugs

Control group: Placebo is injected to the patients of this group. Twenty five Patients with brain tumor, age range of 18 to 60 years and ASA class 1 or 2 are in this group. Saline group will receive 1

Intervention group : Assessment of the effect of Tranexamic acid on intraoperative blood loss , is the purpose. Tranexamic acid will be injected to 25 Patients with brain tumor , age range of 18 to

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Exclusion criteria: Patients with liver, kidney and blood disorders or with previous thrombosis disease; poses of bleeding disorders; abnormal coagulation parameters (prothrombin time and platelet count) ; systolic blood pressure more than 185 on the day of surgery; the patients who were taking aspirin or any kind of anticoagulant a week before the surgery; patients who had history of intracranial arteries surgery and also patients who their surgery will take 3 to 6 hours, will be excluded from study. Inclusion criteria: Brain Tumor; age range of 18 to 60 years; ASA class 1 or 2.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The amount of intraoperative bleeding. Timepoint: Every hour after the intervention. Method of measurement: Through suction container, the number of blood gases and also blood surgical field.	—

Secondary

Measure	Time frame
Comparing EBL between the group which receives TXA and the control group, in patients undergoing craniotomy for tumor excision. Timepoint: 27 hours after the intervention. Method of measurement: Based on hemoglobin levels and by formulation.;Comparing the number of consumed packed cells , between the group which receives TXA and the control group, in patients undergoing craniotomy for tumor excision. Timepoint: 3-8 hours after the intervention. Method of measurement: counting the number of packed cells.;Comparing the amount of bleeding in mL, between the group which receives TXA and the control group, in patients undergoing craniotomy for tumor excision. Timepoint: Every hour after the intervention. Method of measurement: Through suction container, the number of blood gases and also blood surgical field.	—

Measure

Time frame

Comparing EBL between the group which receives TXA and the control group, in patients undergoing craniotomy for tumor excision. Timepoint: 27 hours after the intervention. Method of measurement: Based on hemoglobin levels and by formulation.;Comparing the number of consumed packed cells , between the group which receives TXA and the control group, in patients undergoing craniotomy for tumor excision. Timepoint: 3-8 hours after the intervention. Method of measurement: counting the number of packed cells.;Comparing the amount of bleeding in mL, between the group which receives TXA and the control group, in patients undergoing craniotomy for tumor excision. Timepoint: Every hour after the intervention. Method of measurement: Through suction container, the number of blood gases and also blood surgical field.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPardis Vakili

Ahvaz Jundishapur University Of Medical Sciences, Ahvaz, Iran

vakilipardis@yahoo.comvakili.p@ajums .ac.ir+98 61 3337 5717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026